Home » UPC decisions » Local Division » LD Brussels, July 23, 2026, Decision on Public Access to the Register, UPC_CFI_2192/2026

LD Brussels, July 23, 2026, Decision on Public Access to the Register, UPC_CFI_2192/2026

3 min Reading time

Key takeaways

Granting access to a case file is the general rule and restricting access is the exception (Sec. 7). However, where proceedings are still ongoing, public access to the register requires a “more specific” or “direct legitimate” interest of the applicant to override the interest in protecting the integrity of the proceedings (Sec. 13, with reference to UPC CoA Ocado v Autostore) . Such interest may particularly exist if the applicant is a competitor or licensee with regard to the products within the scope of the patent-in-suit. Also, it would be helpful to specify any client, product or allegation of infringement in relation to the patent in question to meet the threshold for access (Sec. 15).

The mere assertion that the applicant, such as an attorney firm, generally advises “pharmaceutical companies in many areas in technology” and that the proceedings are “highly relevant to Applicant’s business” without identifying any specific client, product or infringement allegation connected to the patent-in-suit does not constitute such a specific interest (Sec. 15).

Division

Local Division Brussels

UPC number

UPC_CFI_2192/2026

Type of proceedings

Application for access to the register (Rule 262.1(b) RoP)

Parties

Applicant: Ter Meer Steinmeister & Partner Patentanwälte mbB

Respondents:

Claimant: Seventy Bio, Inc.

Defendants: Johnson & Johnson, Janssen Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag NV, Janssen Biologics B.V., Janssen-Cilag B.V., Janssen-Cilag GmbH, Janssen-Cilag SAS, Janssen-Cilag SpA, Janssen-Cilag A/S, Janssen-Cilag Aktiebolag, Janssen-Cilag Farmaceutica Lda., Legend Biotech Corporation, Legend Biotech USA Inc., Legend Biotech Ireland Limited, Legend Biotech Belgium BV

Intervener: The United States of America, including the Department of Health an Human Services, Office of Technology Transfer

Patent(s)

EP 3 689 383

Jurisdictions

UPC

Body of legislation / Rules

R. 262.1(b) RoP, Art. 10 UPCA, Art. 45 UPCA


Was the article helpful?


Categories


Tags

Stay in the loop

Never miss a beat by subscribing to the email newsletter. Please see our Privacy Policy.

* = Required field